Business · 29/12/2025

Egis Pharmaceuticals Limited, et al., Face FDA Proposal to Withdraw Approval of Three Abbreviated New Drug Applications

The FDA is proposing to withdraw approval of three Abbreviated New Drug Applications (ANDAs) held by Egis Pharmaceuticals Limited, et al., due to repeated failure to file required annual reports, and is offering the opportunity for a hearing on the proposal.